Elevian develops regenerative medicines that target root-cause aging mechanisms. We are a spin out from Harvard, led by a team of serial entrepreneurs and Harvard scientists.
Elevian’s founders have identified blood factors that regulate aging and stimulate the body’s natural repair and regeneration mechanisms. One well published example, GDF11, reduces age-related cardiac hypertrophy, accelerates skeletal muscle repair, and improves cognitive function in aged mammals. We are developing biotherapeutics that regulate these blood factors.
By targeting root-cause aging mechanisms, Elevian’s therapeutics have the potential to treat or prevent multiple degenerative diseases and extend healthy lifespan.